Citius Oncology, Inc. CTOR Interest Expense, Nonoperating
Interest Expense, Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Citius Oncology, Inc.'s interest expense, nonoperating?
- Citius Oncology, Inc. (CTOR) reported interest expense, nonoperating of $33.03K in Q1 2026.
- What does interest expense, nonoperating mean?
- Represents the costs incurred from borrowing funds, excluding any interest expenses directly tied to core operations. It highlights the company's debt burden and the impact of its capital structure on overall financial performance.